Pharmaceutical
Learn about the latest developments in the pharmaceutical cannabis industry with Business of Cannabis. Discover new drugs, research, and more.
Pharmaceutical · page 13
- Pharmaceutical
Youth not wasted, government-run stores not selling, no mailing vape and dank-e
Youth cannabis use ‘decreased significantly’ in 2021 A federally funded survey revealed that, despite an increasing number of states opening up legal sales, youth consumption of cannabis and illicit substances overall has decreased through the pandemic, reports Marijuana Moment.
- Pharmaceutical
Pfizer enters medical cannabis market with new acquisition
Pharma titan Pfizer is to acquire Arena Pharmaceuticals which has a pipeline in cannabinoid therapeutics.
- Pharmaceutical
‘With Legalisation Gathering Momentum We Are Witnessing The Emergence Of A Global Cannabis Industry’
NEW analysis from Prohibition Partners on the trajectory of the cannabis industry predicts significant global growth over the coming years The ‘The Global Cannabis Report: Second Edition’ estimates 2021 sales of CBD, medical and adult-use cannabis will hit $37.4bn and could rise by 220% to over $105bn by 2026.
- Pharmaceutical
German Pharmaceutical Firm Enters Cannabis Space With Purchase Of Canopy Growth European Asset
FURTHER evidence of pharmaceutical interest in the European cannabis space has emerged with German business Dermapharm Holding acquiring Canopy Growth subsidiary C³ Group.
- Pharmaceutical
Cannabis M&A, lounging in the future and an LSE downturn
Ripe for the Picking | Cannabis M&A predictions for 2022 Low stock prices are likely to motivate more cannabis mergers and acquisitions in 2022, reports Insider.
- Pharmaceutical
London Stock Exchange Cannabis Company Values Down Almost £200m From Early Peaks
THIS has been a transformative year for the European cannabis industry, with growing liberalisation across the continent opening the floodgates for patients and investors alike.
- Pharmaceutical
Global cannabinoid pharmaceuticals market to reach £1.53bn by 2025
The global cannabinoid pharmaceuticals market has been projected to reach £1.53bn (€1.8bn).
- Pharmaceutical
High-Profile Director Quits Oxford Cannabinoid Technologies Board Following Chairman’s Recent Departure
Oxford Cannabinoid Technologies (OCT) has seen its second senior departure in under a month as it begins to recover from the fallout of a credit deal which breached market rules.
- Pharmaceutical
Work To Start On UK Mainland’s First Commercial Cannabis Cultivation Facility For Over 20 Years
GLASS Pharms has agreed a £22.5m funding deal to build the UK mainland’s first, high-THC, commercial cultivation facility for over 20 years.
- Pharmaceutical
First-ever UK EIS and SEIS fund launched for cannabis
An SEIS and EIS fund has been launched in the UK that will target the medical cannabis sector.
- Pharmaceutical
Óskare Capital Announces Launch of First Medical Cannabis SEIS & EIS Fund
Óskare Capital is proud to announce the launch of the first ever SEIS and EIS fundtargeting the Medical and Pharmaceutical Cannabis sector. Óskare Capital UK will advisethe Fund which is managed by Sapphire Capital Partners LLP.
- CBD Market
Concerns over ‘ethically unacceptable’ CBD testing proposed by FSA
A new report has highlighted that the UK industry is struggling under ‘scientifically unjustified, and ethically unacceptable’ toxicity testing for CBD products.
